The mechanisms that drive adaptive resistance in melanoma are primarily composed by resetting the activity of the ERK1/2 pathway, upregulation of receptor tyrosine kinases and upregulation of MIcrophthalmia-associated Transcription Factor (MITF). The gene discussed is MAPK3; the disease is melanoma.